Dr. Rapisuwon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St Nw
Suite C2149
Washington, DC 20010Phone+1 202-687-8901Fax+1 202-444-8829
Summary
- Dr. Suthee Rapisuwon is an oncologist in Washington, DC and is affiliated with multiple hospitals in the area, including MedStar Georgetown University Hospital and MedStar Washington Hospital Center. He received his medical degree from Mahidol University Faculty of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and melanoma and is experienced in malignant melanoma, mucosal melanoma, clinical genetics, cutaneous malignant melanoma, and uveal neoplasms.
Education & Training
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine/Medical Genetics and Genomics, 2007 - 2012- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Medical Genetics and Genomics, 2007 - 2012
Mahidol University Faculty of MedicineClass of 2003
Certifications & Licensure
MD State Medical License 2022 - 2025
DC State Medical License 2012 - 2024
OH State Medical License 2007 - 2013- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Clinical Trials
- A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Start of enrollment: 2017 Jul 26
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Start of enrollment: 2018 Jul 26
Publications & Presentations
PubMed
- 74 citationsDissecting the treatment-naive ecosystem of human melanoma brain metastasis.Jana Biermann, Johannes C Melms, Amit Dipak Amin, Yiping Wang, Lindsay A Caprio
Cell. 2022-07-07 - 126 citationsChronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected MelanomaJ. Randall Patrinely, Rebecca N. Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers
JAMA Oncology. 2021-05-01 - 32 citationsExceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint i...Suthee Rapisuwon, Benjamin Izar, Cory Batenchuk, Alexandre Avila, Shaolin Mei
Journal for Immunotherapy of Cancer. 2019-03-04
Lectures
- Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.2019 ASCO Annual Meeting - 6/1/2019
- Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.2019 ASCO Annual Meeting - 6/1/2019
- Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): I...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
MIBC Tumor Subtypes May Guide Neoadjuvant Chemotherapy UseNovember 30th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
